Added 18 days ago Drug news
Celgene Corporation announced the FDA has accepted the company’s New Drug Application (NDA) for fedratinib and granted a Priority Review....
Added 1 month ago Drug news
CTI BioPharma Corp. will withdraw its application (MAA) to EMA for pacritinib as a treatment for myelofibrosis.
CTI BioPharma Corp. announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment...
Added 6 months ago Drug news
Sierra Oncology, Inc. announces it has acquired momelotinib from Gilead Sciences. for the treatment of myelofibrosis.
Sierra Oncology, Inc. announced it has acquired the drug candidate momelotinib from Gilead Sciences. Momelotinib has been investigated in two...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Philadelphia chromosome negative chronic myeloproliferative neoplasms include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. The new ESMO Clinical Practice Guidelines...
Added 3 years ago
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
Guidelines for myelofibrosis were produced in 2012 (Reilly et al, 2012), but since then Ruxolitinib, a JAK1/JAK2 inhibitor, has been approved for use in the European Union and highly prevalent mutations in the Calreticulin gene (CALR)...
Added 4 years ago
The purpose of this guideline is to provide a practical, rather than a research, approach to the diagnosis, investigation and management of patients with primary myelofibrosis, as well as post-polycythaemic myelofibrosis (post-PV MF) and...
Added 6 years ago
Postpartum hemorrhage is the most common cause of maternal death. Oxytocin is the standard therapy for the prevention of postpartum hemorrhage , but it requires cold storage, which is not available in many countries.
Added 8 months ago
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.
Ascertainment of cases and disease classification is an acknowledged problem for epidemiological research into haematological malignancies.
Added 1 year ago
A rapid increase in awareness of androgen deficiency has led to substantial increases in prescribing of testosterone therapy (TTh), with benefits of improvements in mood, libido, bone density, muscle mass, body composition, energy, and cognition.
Added 1 year ago
Carbetocin RTS for preventing postpartum haemorrhage: a randomized non-inferiority controlled trial (CHAMPION)
A phase III, randomized, double-blind, active, controlled, multinational, multicentre, non-inferiority trial using carbetocin room temperature stable (RTS) for the prevention of postpartum...
Added 8 months ago